There are no Focus articles on APNHF.
There are no Transcripts on APNHF.
There are no News articles on APNHF.
Dec. 31, 2013, 7:04 AM
- GlaxoSmithKline (GSK) has completed the sale of its thrombosis brands, Arixtra and Fraxiparine, to South Africa's Aspen Pharmacare (APNHF) for £700M following regulatory authorization of the transaction.
- The sale fits in with GSK's strategy of focusing on growth products and the delivery of its pipeline. (PR) (Previous)
Jun. 27, 2013, 7:13 AMMerck (MRK) agrees to sell a Dutch active pharmaceutical ingredient business and a portfolio of 11 drug brands to South Africa's Aspen Pharmacare (APNHF.PK) for $1B. The deal follows news last week that Aspen is acquiring GlaxoSmithKline's Arixtra and Fraxiparine/Fraxodi brands of thrombosis drugs in a transaction that could be worth $1B. (PR) | Comment!
Jun. 18, 2013, 9:43 AMMore on GSK (GSK -0.3%) / Aspen (APNHF.PK) deal: Reuters speculates that GSK's sale of its thrombosis drug brands Arixtra and Fraxiparine to Aspen could be worth £700M, or twice this year's anticipated sales of around £350M. That would be down from £420M in 2013 and £510M in 2011. Around 1,000 GSK workers, mostly in France, would transfer to Aspen. News of the prospective sale prompted speculation that GSK may look to offload other older drugs. | Comment!
Jun. 18, 2013, 8:33 AMGlaxoSmithKline (GSK) has received an offer from South Africa's Aspen Pharmacare (APNHF.PK) for its thrombosis drug brands Arixtra and Fraxiparine (excluding China, India and Pakistan), and the related manufacturing site. GSK said any sale would fit in with its strategy of focusing on growth products and the delivery of its pipeline. (PR) | Comment!
Aug. 15, 2012, 8:43 AM
Aug. 16, 2010, 7:23 AM
There are no StockTalks on this stock yet.
APNHF vs. ETF Alternatives